- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01715623
Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies. (PRIERR)
The investigators previously showed that both antibody class switching (from IgM to IgG, IgA or IgE) and antibody secretion are controlled by a polymorphic "3' regulatory region" (3'RR) of the immunoglobulin heavy chain (IgH) locus. Alleles of the 3'RR have shown influences on the severity and progression of IgA nephropathy (IgAN) (with an over-representation of the B allele among patients with severe kidney IgA deposits). Allele B also constitutes a risk factor for celiac disease, herpetiform dermatitis, psoriasis and rheumatoid arthritis. Since the 3'RR now appears as a crucial regulator of Ig production, we wish to check whether its genetic polymorphism might influence not only the occurrence of immunopathologic processes involving class-switched antibody deregulated production but also the severity of such diseases or the time course of their progression. We wish to focus on two conditions involving class-switched antibodies: on one hand the severe forms of IgE hypersensitivities, and on the other hand a disease involving pathogenic IgA and for which the prognosis is currently very difficult to predict at the onset of the disease: Henoch-Schonlein purpura (HSP).
Regarding hypersensitivities, the diversity of their clinical manifestations prompt us to focus on homogeneous groups of patients and we thus wish to concentrate on two groups of patients who are frequently referred to the hospital: severe allergies to Hymenoptera venoms and severe food allergies related to peanut allergens sensitization. These groups will be built by considering multiple clinical criteria (clinical history, severity of the manifestations, positive skin tests, and positive oral provocation tests for peanut allergens…) and biological criteria authenticating the mechanisms of the disease (high specific serum IgE, demonstration of specific basophil activation by the allergen…).
In parallel to the study in patients, we will include a large cohort of healthy controls (400 individuals), in order to be able to decipher whether correlations can be seen between:
- IgH 3'RR genotypes
- The serum accumulation of the various Ig classes, including IgG subclasses, IgA (which are sometimes depicted as protective, sometimes as tolerogenic and anti-inflammatory) and IgE (highly pro-inflammatory and responsible for hypersensitivities)
- IgG allotypes (with 6 frequent IgG haplotypes known in human and previously reported as correlated with varying levels of IgG and IgE production in normal individuals).
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
This study should thus finally provide answers to 5 questions which are currently un-addressed:
- How the 3'RR alleles are linked to IgG allotypes and corresponding IgH haplotypes?
- Is there a physiological link between 3'RR alleles and production of the various Ig classes and sub-classes?
- Is the 3'RR polymorphism connected with the risk of more severe forms of allergic diseases?
- Is the 3'RR polymorphism connected with the risk of occurrence and/or severe evolution of HSP?
- Is the oncogenicity of translocations affecting the IgH locus connected to the strength of the 3'RR allelic variants?
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Limoges, Frankreich, 87042
- Clinical Investigation Center
-
Limoges, Frankreich, 87042
- Nephrology
-
Limoges, Frankreich, 87042
- Pediatric
-
Limoges, Frankreich, 87042
- Pneumology
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
4 populations :
- Healthy Volunteers
- subjects with HPS
- subjects with peanut allergy or hymenoptera venom allergy
- lymphoma (biological collection)
Beschreibung
Inclusion Criteria:
- Healthy Volunteers:
Age ≥ 18 and < 50 years No history of allergy, haematological malignancies or immune diseases
- Subjects with allergy:
- Children:
Age ≥ 4 and < 18 years Clinical history supporting the diagnosis of severe food allergy Peanut specific IgE (Arah2) -Adults: Age > 18 and < 60 years History of severe reaction after antigenic challenge Anaphylactic shock already experienced Specific IgE or positive BAT Positive prick tests
- subject with HPS:
- Children:
Age ≥ 4 and < 18 years Henoch Schonlein Purpura (HSP) documented by Ankara 2008 criteria
-Adult: Henoch Schonlein Purpura(HSP) with renal involvement Adults ≥ 18 years,
Exclusion Criteria:
- subject with allergy or subject with Henoch Schonlein Purpura(HSP): known pregnancy patient under guardianship
- Healthy Volunteers:
Allergy known pregnancy patient under guardianship
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Children with HSP
children with Purpura of Henoch-Schönlein with or without renal complication
|
Dosage of Ig
|
|
healthy volunteers
healthy volunteers without allergy
|
Dosage of Ig
|
|
subjects with allergy
subjects with peanut allergy or hymenoptera venom allergy
|
Dosage of Ig
|
|
lymphoma
lymphoma-proliferation with chromosome 14 translocation
|
Dosage of Ig
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
the percentage of allele B
Zeitfenster: one day
|
A comparison will be made of the percentage of allele B between healthy volunteers and the three cohorts of subjects with various diseases: (1) lymphoma (lymphoma-proliferation with chromosome 14 translocation ), (2) Henoch-Schonlein purpura HSP (3), allergy (peanut and Hymenoptera venom)
|
one day
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Michel COGNE, MD, Limoges UH
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- I12002 PRIERR
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lymphom
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten
Klinische Studien zur a blood sample
-
Hillel Yaffe Medical CenterUnbekannt
-
Haydarpasa Numune Training and Research HospitalAbgeschlossenBlutgerinnungsstörungTruthahn
-
University Hospital, CaenAbgeschlossen
-
TCI Co., Ltd.AbgeschlossenDermatologieTaiwan
-
HemanextAbgeschlossenVollblutspende und LeukoreduktionVereinigte Staaten
-
University of UtahAlbert Einstein College of Medicine; University of California, San Francisco; National... und andere MitarbeiterAbgeschlossen
-
University Hospital, RouenRekrutierungHepatitis B | Hepatitis C | AIDSFrankreich
-
University Hospital, BonnAbgeschlossenPostoperative Schmerzen | Muskelatrophie | Spondylolisthese | SpondylodiskitisDeutschland
-
Centre Hospitalier Princesse GraceAbgeschlossen
-
George Fox UniversityUnbekanntMuskelschwäche | Kann eine Therapie zur Einschränkung des Blutflusses den Kraftzuwachs in der Rotatorenmanschette steigern?Vereinigte Staaten